A new tablet helped people with type 2 diabetes lose up to 8% of body weight.
Researchers tested the drug orforglipron against oral semaglutide for one year.
Orforglipron improved blood sugar control and reduced weight more strongly.
Patients took it without fasting, which simplified daily use.
More participants stopped treatment because of stomach-related side effects.
Regulators have not yet approved the drug in major markets.
Experts see major potential for easier and cheaper obesity therapies.
They expect powerful incretin tablets to reshape diabetes care within a decade.
